Nevro to Highlight New Clinical Evidence at the 2021 North American Neuromodulation Society Virtual Meeting
January 14, 2021 at 07:00 am EST
Share
Nevro Corp. announced a series of data presentations supporting the use of the company's HF10® therapy for patients with chronic pain. Results will be presented at the 2021 North American Neuromodulation Society (NANS) Virtual Meeting held from January 14-16, 2021. This year a total of 20 scientific abstracts reviewing clinical results with HF10 therapy, consisting of two late-breaking abstract presentations and 18 e-poster abstracts, will be presented at NANS 2021. The broad range of research investigates both new and established pain areas, opioid reduction, programming versatility with paired waveforms and real-world capability for HF10 therapy to help patients failing traditional spinal cord stimulation. Key amongst these presentations will be data for the SENZA-Painful Diabetic Neuropathy (PDN) randomized clinical trial (RCT) and a first look at results from the Non-Surgical Refractory Back Pain (NSRBP) RCT: Painful Diabetic Neuropathy (PDN) – Nevro's PDN trial is the largest PDN RCT of SCS treatment conducted thus far with 216 randomized subjects. The data presented will extend the primary endpoint outcomes presented at NANS in January 2020, highlighting complete 6-month results and analysis of all prespecified secondary endpoints. Additionally, a first look at 12-month pain relief and preliminary crossover results will be included. Data from the SENZA-PDN trial formed the basis of the company's recent PMA supplement submission to the FDA, which if approved, will provide an innovative treatment option to patients who are unable to find relief with currently available treatment options. Dr. Erika Petersen, Professor of Neurosurgery and Director of Functional and Restorative Neurosurgery at the University of Arkansas for Medical Sciences, and lead Principal Investigator for the SENZA-PDN study, will present the results on January 15, 2021, from 4:53-5:05 pm Central Time, during the NANS 2021 Late-Breaking Abstract Plenary Session 1. Non-Surgical Refractory Back Pain(NSRBP) – Nevro's NSRBP data presentation will include 3-month primary endpoint results from this RCT investigating spinal cord stimulation efficacy in Non-Surgical Refractory Back Pain, with 159 randomized subjects from 15 study centers. Results will be presented by Leonardo Kapural, MD, PhD, Medical Director for the Carolinas Pain Institute, on January 15, 2021, from 4:17-4:29 pm Central Time, at NANS 2021 Late-Breaking Abstract Plenary Session 1.
Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.